MJFF’s Therapeutics Pipeline Program (TPP), launched in June 2012, will support research projects focused on developing therapeutic treatments for Parkinson’s disease, specifically at the pre-clinical and clinical stages of research. TPP funds research at these stages of research particularly because they are “an area where projects often falter due to lack of support,” according to MJFF’s Associate Director of Research Programs, Sonal Das, PhD. In a recent interview with Biotechnology Industry Organization (BIO), Dr. Das further explained that by sharing the risk of drug development with researchers, we can keep promising research moving forward. Listen to the entire interview here.
The deadline for academic and industry researchers to apply to the Therapeutics Pipeline Program is this coming Wednesday, September 12.